Keith A. Delman, MD | Authors

RITEAID

38375 AMARYLLIS PL

Articles

Ipilimumab for Advanced Melanoma: Let’s Not Throw Caution to the Winds

December 15, 2010

The authors provide a timely and relevant review of the role that the immune system plays in regulating tumor growth and how immune modulation can alter tumor response. This review follows from the recently published phase III trial of ipilimumab,[1] a monoclonal antibody to cytotoxic T-lymphocyte antigen 4 (CTLA-4) and the first therapy in several decades to produce prolonged overall survival (OS) in patients with metastatic melanoma. While this outcome underscores the importance of this therapy in treating metastatic melanoma, its clinical applicability, at least on a widespread level, necessitates further exploration.

Aggressive Surgical Therapy for Metastatic Disease Is Appropriate in the Current Management of Melanoma

January 01, 2009

Small bowel metastases from melanoma are uncommon. While the authors reference two studies that reported a large proportion of patients with small bowel metastases, the true incidence of gastrointestinal (GI) lesions in melanoma patients is much lower.